Healius Ltd (ASX:HLS) has become the latest healthcare stock to unsettle investors, with the pathology provider plunging to fresh all-time lows after downgrading earnings guidance and warning deteriorating conditions across the sector were squeezing margins harder than expected.
Shares in the ASX-listed pathology services company fell as much as 20% on Wednesday after the company cut FY26 underlying EBITDA guidance to $259 million–264 million, below market expectations of roughly $271 million, while underlying EBIT guidance of $30 million–35 million came in well short of forecasts.
The company blamed softer pathology volumes, weaker GP attendance trends and rising labour costs, while also flagging mounting pressure from the Fair Work Commission’s gender undervaluation ruling.
The timing has only added to an already shaky mood hanging over the ASX healthcare sector following CSL Limited (ASX:CSL)’s sharp sell-off earlier this week, which rattled investor confidence across the broader healthcare complex.
Pathology pressure builds
Healius’ update painted a difficult picture for Australia’s pathology industry, where providers are attempting to manage rising operating costs alongside sluggish testing volumes and limited funding relief.
The company said pathology volumes grew 1.2% during the first half of FY26, but weakened over the broader financial year-to-date period, with volumes down 0.4% for the 10 months to April despite revenue growth of 2.4%. GP attendances also declined during the period.
At the same time, labour costs are continuing to rise.
Healius warned the Fair Work Commission’s initial gender undervaluation findings would add another $1.8 million to pathology labour costs in the fourth quarter alone, with further wage increases scheduled from January 2027 and phased increases for health professionals beginning from July this year.
Management also used the update to criticise Tuesday night’s federal budget, arguing it delivered no meaningful new funding support for pathology providers despite the sector already operating under long-running indexation freezes for most tests.
The company warned ongoing funding pressure was already forcing difficult decisions across the sector, including staff reductions, collection centre closures and pressure on regional laboratories. It also flagged out-of-pocket pathology fees as one of the few remaining options available to offset rising costs.
For investors, the downgrade reinforced growing concerns that healthcare providers are losing some of the earnings resilience traditionally associated with the sector.
One bright spot amid the sell-off
There was at least some better news in Healius’ announcement, with the company saying its contract research business Agilex Biolabs continued to perform strongly, with revenue up 13.7% year-to-date.
Healius also announced a strategic review of the business after receiving several unsolicited approaches from interested parties, appointing UBS to assist in exploring a potential sale process.
But that was largely overshadowed by the broader tone of Wednesday’s update — and by the growing sense that the ASX healthcare sector is going through one of its toughest stretches in years.
CSL shock still reverberating
Healius’ sell-off comes only days after CSL delivered one of the worst sessions in the company’s history, with the biotech giant tumbling more than 15% on Monday after another major impairment and disappointing guidance update.
CSL’s downgrade has continued to weigh heavily on broader healthcare sentiment this week, with investors reassessing earnings expectations and sector valuations after one of the biotech giant’s worst market reactions in years. The stock is now down roughly 20% this week, helping drag the healthcare index lower alongside weakness in names including Telix Pharmaceuticals, Pro Medicus and ResMed.
The broader weakness has been notable partly because healthcare is typically viewed as one of the market’s more defensive sectors — a place investors often rotate towards during periods of economic uncertainty.
Instead, the sector is increasingly facing many of the same problems hitting other industries: labour inflation, cost pressures, reimbursement challenges and growing scrutiny around valuations after years of strong performance.